Filing Flows › Comparisons › BTAIQ vs PBLS
BioXcel Therapeutics vs Parabilis Medicines: BTAIQ and PBLS compared
BioXcel Therapeutics is the larger company: $182K of revenue in its latest quarter (Q2 2026) against $148K for Parabilis Medicines (Q2 2026).
Where the money goes: BTAIQ and PBLS
BioXcel Therapeutics (BTAIQ) · Q2 2026
BioXcel Therapeutics, Q2 2026: revenue $182K (+52% year over year), net loss $14.7M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
Parabilis Medicines (PBLS) · Q2 2026
Parabilis Medicines, Q2 2026: revenue $148K, net loss $52.5M. The chart follows the revenue to costs, profit and cash.
| BioXcel Therapeutics (BTAIQ) | Parabilis Medicines (PBLS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $182K | $148K |
| Revenue growth, Y/Y | +52% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$14.7M | −$52.5M |
| Operating cash flow | −$6.1M | — |
Questions
Which is bigger, BioXcel Therapeutics or Parabilis Medicines?
BioXcel Therapeutics is the larger company: $182K of revenue in its latest quarter (Q2 2026) against $148K for Parabilis Medicines (Q2 2026).
More: BioXcel Therapeutics earnings · how BioXcel Therapeutics makes money · Parabilis Medicines earnings · how Parabilis Medicines makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.